BR0207267A - Proteìnas artificiais com imunogenicidade reduzida - Google Patents

Proteìnas artificiais com imunogenicidade reduzida

Info

Publication number
BR0207267A
BR0207267A BR0207267-0A BR0207267A BR0207267A BR 0207267 A BR0207267 A BR 0207267A BR 0207267 A BR0207267 A BR 0207267A BR 0207267 A BR0207267 A BR 0207267A
Authority
BR
Brazil
Prior art keywords
fusion proteins
relates
molecule
molecules
reduced immunogenicity
Prior art date
Application number
BR0207267-0A
Other languages
English (en)
Inventor
Stephen Gillies
Francis
J Carr
Tim Jones
Graham Carter
Anita Hamilton
Stephen Williams
Marian Hanlon
John Watkins
Matthew Baker
Jeffrey C Way
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0207267A publication Critical patent/BR0207267A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

"PROTEìNAS ARTIFICIAIS COM IMUNOGENICIDADE REDUZIDA". A invenção refere-se às proteínas artificiais modificadas, preferivelmente as proteínas de fusão, tendo uma imunogenicidade reduzida em comparação com a molécula não-modificada de origem quando expostas a uma espécie in vivo. A invenção refere-se, acima de tudo, às novas proteínas de fusão de imunoglobulina, as quais essencialmente consistem em uma molécula de imunoglobulina, ou um fragmento da mesma, covalentemente fundida por meio de sua extremidade de C à extremidade de N de uma molécula que não é de imunoglobulina biologicamente ativa, preferivelmente um polipeptídeo ou proteína ou um seu fragmento biologicamente ativo. Em uma modalidade específica, a invenção refere-se às proteínas de fusão consistindo em uma porção Fc de um anticorpo que está fundido, como mencionado, à molécula-alvo não-imunológica, o que faz surgir eficácia biológica ou farmacológica. As moléculas da invenção têm seq³ências de aminoácidos que são alteradas em uma ou mais posições de resíduos de aminoácidos, porém têm, no básico, a mesma atividade biológica em comparação com as moléculas não-alteradas. As mudanças são feitas em regiões das moléculas que são identificadas como epítopos de células T, que contribuem para uma reação imune em um hospedeiro vivo. Assim, a invenção também refere-se a um novo método para a preparação de tais proteínas de fusão por identificação dos ditos epítopos, compreendendo o cálculo dos valores de epítopos de células T para os locais de ligação às moléculas de MHC da Classe II em um peptídeo por métodos auxiliados por computador.
BR0207267-0A 2001-02-19 2002-02-18 Proteìnas artificiais com imunogenicidade reduzida BR0207267A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01103955 2001-02-19
EP01108291 2001-04-05
PCT/EP2002/001690 WO2002066514A2 (en) 2001-02-19 2002-02-18 Artificial fusion proteins with reduced immunogenicity

Publications (1)

Publication Number Publication Date
BR0207267A true BR0207267A (pt) 2004-02-10

Family

ID=26076484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207267-0A BR0207267A (pt) 2001-02-19 2002-02-18 Proteìnas artificiais com imunogenicidade reduzida

Country Status (13)

Country Link
US (2) US7189830B2 (pt)
EP (1) EP1361891A2 (pt)
JP (1) JP2004532620A (pt)
KR (1) KR20040074587A (pt)
CN (1) CN100522242C (pt)
AU (1) AU2002233340B2 (pt)
BR (1) BR0207267A (pt)
CA (1) CA2438628A1 (pt)
HU (1) HUP0303171A2 (pt)
MX (1) MXPA03007323A (pt)
PL (1) PL362324A1 (pt)
RU (1) RU2363707C2 (pt)
WO (1) WO2002066514A2 (pt)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312188C (en) 1997-12-08 2010-06-29 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
BR9909583A (pt) * 1998-04-15 2002-01-15 Lexigen Pharm Corp Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
US6548653B1 (en) * 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DK1252192T3 (da) * 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
BR0112111A (pt) * 2000-06-29 2003-05-06 Merck Patent Gmbh Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina
MXPA03008031A (es) * 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DK1383785T3 (da) * 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
ES2327409T3 (es) 2003-03-26 2009-10-29 Apogenix Gmbh Proteinas de fusion fc mejoradas.
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1673398B1 (en) 2003-10-16 2010-12-29 Micromet AG Multispecific deimmunized cd3-binders
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
KR20050047030A (ko) 2003-11-13 2005-05-19 한미약품 주식회사 약물의 캐리어로서 유용한 IgG Fc 단편 및 그의제조방법
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질
AU2005203962C1 (en) 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
EP1706428B1 (en) 2004-01-22 2009-09-23 MERCK PATENT GmbH Anti-cancer antibodies with reduced complement fixation
US7674464B2 (en) * 2004-03-04 2010-03-09 The University Of Tennessee Research Foundation Intracellular interleukin-1 receptor antagonists
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
US20090060925A1 (en) * 2004-08-03 2009-03-05 The Trustees Of Columbia University In The City Of Rage Fusion Proteins and Methods of Use
EP1781700B1 (en) 2004-08-03 2014-03-19 TransTech Pharma, LLC Rage fusion proteins and methods of use
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2325207B1 (en) 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
KR20070085886A (ko) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 감소된 면역원성의 il-7 변이체
US20060275282A1 (en) * 2005-01-12 2006-12-07 Xencor, Inc. Antibodies and Fc fusion proteins with altered immunogenicity
CA2597584A1 (en) * 2005-02-15 2006-08-24 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
WO2007041317A2 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
CN101360759A (zh) 2005-11-07 2009-02-04 哥本哈根大学 神经营养因子衍生的肽序列
ES2595091T3 (es) 2005-12-21 2016-12-27 Amgen Research (Munich) Gmbh Composiciones farmacéuticas con resistencia a CEA soluble
BRPI0620380B1 (pt) * 2005-12-23 2018-04-24 Gcoder Systems Ab Padrão de posicionamento
ATE555125T1 (de) * 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
JP2009521912A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 低減された免疫原性を有する抗cd19抗体
NZ569545A (en) * 2006-02-09 2011-11-25 Transtech Pharma Inc Rage fusion proteins and methods of use for treating inflammation
US8293500B2 (en) 2006-03-22 2012-10-23 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
CN100402551C (zh) * 2006-04-14 2008-07-16 中国科学院长春应用化学研究所 β2-微球蛋白的抗原表位及应用
WO2007130302A2 (en) * 2006-05-05 2007-11-15 Transtech Pharma, Inc. Rage fusion proteins, formulations, and methods of use thereof
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
JP2009537145A (ja) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのcd47と関連した組成物および方法
WO2008045380A2 (en) * 2006-10-04 2008-04-17 Codon Devices, Inc. Nucleic acid libraries and their design and assembly
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
WO2009014835A2 (en) * 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc FC variants with modified binding to FCRN
EP2769991B1 (en) * 2008-01-03 2018-08-22 The Scripps Research Institute Antibody targeting through a modular recognition domain
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
US20110160071A1 (en) * 2008-06-03 2011-06-30 Baynes Brian M Novel Proteins and Methods for Designing the Same
US8734795B2 (en) 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
WO2010096838A2 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Llc Proproteins and methods of use thereof
CN101863982A (zh) * 2009-04-17 2010-10-20 哈药集团生物工程有限公司 一种用于升高血小板的融合蛋白及其制备方法
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
WO2011002673A1 (en) * 2009-07-01 2011-01-06 Temple University - Of The Commonwealth System Of Higher Education Leptin agonist and methods of use
EP3636759B1 (en) 2009-07-17 2023-10-11 BioAtla, Inc. Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
WO2011098095A1 (en) * 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
JP5840148B2 (ja) 2010-03-04 2016-01-06 フェニックス インク. 変性させることなく可溶性組換えインターフェロンタンパク質を産生する方法
EP2552949B1 (en) 2010-04-01 2016-08-17 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell
ES2826445T3 (es) * 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
SG10201902596TA (en) 2010-07-16 2019-04-29 Bioatla Llc Novel methods of protein evolution
CA2823044C (en) 2010-12-31 2022-08-16 Jay M. Short Express humanization of antibodies
AU2011352207B2 (en) 2010-12-31 2016-03-03 Bioatla, Llc Comprehensive monoclonal antibody generation
JP5979673B2 (ja) * 2011-02-18 2016-08-24 国立大学法人京都大学 タンパク質水溶液
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
KR20140100543A (ko) 2011-11-29 2014-08-14 뉴로페이지 파마슈티컬즈, 인크. 박테리오파아지 유전자 3 단백질 조성물 및 아밀로이드 결합제로서의 용도
US9969813B2 (en) 2012-05-10 2018-05-15 Bioatla, Llc Multi-specific monoclonal antibodies
ES2641373T3 (es) 2012-10-02 2017-11-08 Proclara Biosciences, Inc. Uso de P3 de proteínas de fusión de bacteriófagos como agentes de unión amiloides
WO2014150600A2 (en) 2013-03-15 2014-09-25 Angelica Therapeutics, Inc. Modified toxins
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
EP3003349B1 (en) 2013-05-28 2018-12-12 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
NZ715455A (en) 2013-07-09 2021-12-24 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
EP2840091A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP3447493B1 (en) 2014-01-07 2020-05-13 Bioatla, LLC Proteins targeting orthologs
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR20160131073A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg4-5에 대해 특이적인 항-라미닌4 항체
US20170002077A1 (en) * 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
KR20150140177A (ko) * 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
BR112017009297B1 (pt) * 2014-11-05 2024-02-15 Annexon, Inc Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
AU2015358504A1 (en) 2014-12-03 2017-06-29 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal
JP6907199B2 (ja) * 2015-10-30 2021-07-21 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. D−タンパク質リガンドの構造ベース設計
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN115260310A (zh) 2015-11-24 2022-11-01 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
GB201607521D0 (en) * 2016-04-29 2016-06-15 Oncolmmunity As Method
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US20200123198A1 (en) * 2016-10-04 2020-04-23 The Council Of The Queensland Institute Of Medical Research (Qimr) Peptide Libraries and Methods of Use
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
JP6925431B2 (ja) * 2016-11-09 2021-08-25 フィロジェン エッセ.ピー.アー. Il2及びtnf突然変異体のイムノコンジュゲート
CN110913881A (zh) * 2017-03-14 2020-03-24 加利福尼亚大学董事会 工程化crispr cas9免疫隐身
WO2019014650A1 (en) * 2017-07-13 2019-01-17 City Of Hope ANTICANCER CONJUGATES OF PEPTIDE COUPLED WITH PHOSPHOROTHIOATE AND METHODS OF USE THEREOF
US11541121B2 (en) 2017-07-13 2023-01-03 City Of Hope Phosphorothioate-conjugated peptides and methods of using the same
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
JP2022503959A (ja) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド Il-12ヘテロ二量体fc-融合タンパク質
AU2020358979A1 (en) 2019-10-03 2022-04-21 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
CN112457399B (zh) * 2020-12-19 2023-09-01 上海佰君生物科技有限公司 一种人免疫球蛋白g的提纯方法
CN112466390B (zh) * 2020-12-19 2023-11-14 广东众源药业有限公司 可用于纯化人免疫球蛋白g的疏水性环状肽配基
CN115724988B (zh) * 2021-08-26 2023-11-17 瑅安生物医药(杭州)有限公司 一种接近天然分子的多肽融合分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
DE19822406A1 (de) 1998-05-19 1999-11-25 Alexander Cherkasky Therapeutisches Präparat: Monoklonale Immunogenische Protease (MIP)/Monoklonales Immunogenisches Chymotrypsin (MIC)
ATE352559T1 (de) * 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
BR0007414A (pt) * 1999-01-07 2001-10-16 Lexigen Pharm Corp Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
DE19925052B4 (de) 1999-06-01 2012-01-12 Alexander Cherkasky Proteinkomplexe für den zielgerichteten Transport von (Poly)Peptide und Nukleinsäuren und sequenzspezifische Integration von DNA-Vektoren
HUP0303173A2 (hu) * 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok
DE10133071A1 (de) 2001-07-07 2003-03-06 Alexander Cherkasky Antigene, Rezeptoren, Liganden oder ihre Regionen kombiniert mit proteolytischer Aktivität

Also Published As

Publication number Publication date
WO2002066514A3 (en) 2003-02-13
RU2363707C2 (ru) 2009-08-10
US7189830B2 (en) 2007-03-13
AU2002233340B2 (en) 2008-05-22
KR20040074587A (ko) 2004-08-25
MXPA03007323A (es) 2003-12-12
EP1361891A2 (en) 2003-11-19
US20040082039A1 (en) 2004-04-29
JP2004532620A (ja) 2004-10-28
CN1492768A (zh) 2004-04-28
CA2438628A1 (en) 2002-08-29
CN100522242C (zh) 2009-08-05
US20070269435A1 (en) 2007-11-22
WO2002066514A2 (en) 2002-08-29
HUP0303171A2 (hu) 2003-12-29
US7615217B2 (en) 2009-11-10
RU2003127387A (ru) 2005-03-27
PL362324A1 (en) 2004-10-18

Similar Documents

Publication Publication Date Title
BR0207267A (pt) Proteìnas artificiais com imunogenicidade reduzida
Südhof et al. Cassette of eight exons shared by genes for LDL receptor and EGF precursor
Rosenberg Protein analysis and purification: benchtop techniques
CN108289941B (zh) 用于消除对治疗剂的免疫应答的改进的方法和化合物
Morris et al. Isolation and characterization of human calcitonin gene-related peptide
Smithies et al. Dog homologue of human β2-microglobulin
Hirano et al. Design and synthesis of a homogeneous erythropoietin analogue with two human complex‐type sialyloligosaccharides: combined use of chemical and bacterial protein expression methods
Haniu et al. Human Leptin Receptor: DETERMINATION OF DISULFIDE STRUCTURE ANDN-GLYCOSYLATION SITES OF THE EXTRACELLULAR DOMAIN
NO975435L (no) Modifiserte/kimeriske proteiner samt anvendelse derav
Macmillan et al. Solid-phase synthesis of thioether-linked glycopeptide mimics for application to glycoprotein semisynthesis
Keller et al. Abalone (Haliotis tuberculata) hemocyanin type 1 (HtH1) Organization of the≈ 400 kDa subunit, and amino acid sequence of its functional units f, g and h
Lanzillotti et al. The 10 kDa domain of human erythrocyte protein 4.1 binds the Plasmodium falciparum EBA-181 protein
US5989554A (en) High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
Luo et al. Residues 48 and 82 at the N-terminal hydrophobic pocket of rabbit skeletal muscle troponin-C photo-cross-link to Met121 of troponin-I
Zal et al. Investigation by electrospray ionization mass spectrometry of the extracellular hemoglobin from the polychaete annelid Alvinella pompejana: an unusual hexagonal bilayer hemoglobin
JP2004520836A (ja) 低減された免疫原性を有する修飾されたプロタミン
Barron-Casella et al. Expression and Purification of Functional Recombinant Epitopes for the Platelet Antigens, PIA1 and PIA2
US20060217302A1 (en) Paralytic peptide for use in neuromuscular therapy
US6764689B1 (en) High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
JP2803184B2 (ja) 酸性線維芽細胞成長因子の抗体,その用途およびペプチド
Robinson et al. Characterization of a novel glycoprotein isolated from the basement membrane matrix of the Engelbreth-Holm-Swarm tumor
Galat et al. Subunit of glycosylation-inhibiting factor is an abundant protein that binds to certain glycoproteins and sugars
Rosenberg Protein Analysis
ES2351685T3 (es) Proteína similar a la proteína específica neuroendocrina y adnc codificante.
Dellaratta et al. Characterization of rabbit antisera elicited with human LMP2‐and LMP7‐specific peptides and recombinant proteins

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.